Functional imaging of HER2-positive metastatic breast cancer using 64Cu DOTA-trastuzumab positron emission tomography (PET)

被引：0
|
作者：
Mortimer, Joanne E.
Conti, Peter
Tong, Shan
Reyes, Jose
Carroll, Mary I.
Poku, Kofi
Colcher, David
Raubitschek, Andrew Antony
Bading, James R.
Miles, Joshua
机构：
[1] City Hope Canc Ctr, Beckman Res Inst, Duarte, CA USA
[2] USC, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
639
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [22] Kinetics of Nanoparticle Radiolabeling of Metalloporphyrin with 64Cu for Positron Emission Tomography (PET) Imaging
    Wang, Leon Z.
    Lim, Tristan L.
    Padakanti, Prashanth K.
    Carlin, Sean D.
    Alavi, Abass
    Mach, Robert H.
    Prud'homme, Robert K.
    INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, 2020, 59 (43) : 19126 - 19132
  • [23] 64Cu-DOTA-trastuzumab imaging in a HER2-positive intracranial patient-derived xenograft (PDX) model of breast cancer metastasis
    Kristensen, Lotte
    Nielsen, Carsten
    Nedergaard, Mette
    Knudsen, Camilla
    Christensen, Camilla
    Wick, Michael
    Papadopoulos, Kyri
    Tolcher, Anthony
    Kjaer, Andreas
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [24] Relationship between 64Cu-DOTA-trastuzumab positron emission tomography uptake and assessment of HER2 by immunohistochemistry in women with advanced breast cancer
    Mortimer, J. E.
    Colcher, D.
    Frankel, P.
    Raubitschek, A.
    Carroll, M.
    Conti, P.
    Tong, S.
    Poku, K.
    Miles, J.
    Bading, J.
    CANCER RESEARCH, 2013, 73
  • [25] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [26] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 9 - 11
  • [27] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
  • [28] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [29] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [30] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
12345